IOBT IO Biotech, Inc.
USHealthcareAs of 2026-04-09 09:30
Why IOBT matters now
IO Biotech, Inc. (IOBT) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.01 with -27.59% on the session and $885.7K in market capitalization; recent performance reads 1-month +0.00% and YTD -97.98%.
The latest financial table shown here is Q3 2025, with revenue of $0.00, net income of $-8.4M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9152.8%.
The latest indexable market news headline is "IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analysts" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $0.50. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.90
P/S
0.00
EV/EBITDA
0.32
DCF Value
$0.83
FCF Yield
-9152.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-465.4%
ROA
-221.1%
ROIC
-406.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-8.4M | $-0.13 |
| Q2 2025 | $0.00 | $-26.2M | $-0.40 |
| Q1 2025 | $0.00 | $-22.4M | $-0.34 |
| Q4 2024 | $0.00 | $-31.3M | $-0.48 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$0.50
Target (Median)
$0.50
Target Range
$0.50 - $0.50
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
DK
Exchange
—
Beta
0.89
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.